Ependymoma malignant – Diagnostics – Overview of Information and Clinical Research

Diagnosing malignant ependymoma involves a combination of medical history, physical examinations, imaging tests, and laboratory analysis to confirm the presence and type of tumor. Early and accurate diagnosis helps doctors plan the best treatment approach and improve outcomes for patients facing this challenging condition.

Introduction: Who Should Seek Diagnostic Testing

If you or someone you care about begins experiencing persistent or unusual symptoms that affect daily life, it may be time to seek medical attention. Malignant ependymoma, a type of tumor that grows in the brain or spinal cord, can cause a wide range of symptoms depending on where it develops. These tumors form from cells that line the fluid-filled spaces in the brain and the canal of the spinal cord. Because the symptoms can vary greatly, knowing when to seek help is important.^[1]

People with an ependymoma in the brain might notice headaches that won’t go away, nausea, vomiting, blurry vision, confusion, seizures, or changes in behavior and mood. Children may become unusually irritable or have trouble concentrating, and babies might have a larger-than-usual head or spit up more than normal. When the tumor is located in the spinal cord, symptoms can include neck or back pain, weakness in the arms or legs, numbness, tingling, and problems with bladder or bowel control.^[1]^[2]

It’s advisable to see a doctor if these symptoms appear suddenly, worsen over time, or interfere with normal activities. While many of these signs can be caused by less serious conditions, only proper diagnostic testing can determine whether an ependymoma or another medical issue is responsible. Early diagnosis allows for timely treatment, which can make a significant difference in managing the disease and improving quality of life.^[3]

Both children and adults can develop ependymomas, though the location of the tumor often differs. In children, most ependymomas appear in the lower back part of the brain near the cerebellum. In adults, these tumors more commonly form in the spinal cord. Regardless of age or location, seeking medical evaluation when symptoms arise is a critical first step toward understanding what is happening in the body.^[2]^[4]

Diagnostic Methods for Identifying Ependymoma

Diagnosing malignant ependymoma is a process that begins with a conversation between the patient and the doctor. The doctor will ask detailed questions about the symptoms, how long they have been present, and whether there is any family history of brain tumors or genetic conditions. This medical history helps the doctor understand what might be causing the symptoms and which tests are needed next.^[4]

A neurological exam is usually performed early in the diagnostic process. During this exam, the doctor checks vision, hearing, balance, coordination, strength, and reflexes. Problems in any of these areas can give clues about which part of the brain or spinal cord might be affected by a tumor. For example, weakness on one side of the body or trouble walking might suggest pressure on certain nerves or brain regions.^[14]

The next important step involves imaging tests, which allow doctors to see inside the body without surgery. A magnetic resonance imaging (MRI) scan is the most commonly used test for diagnosing ependymomas. MRI creates detailed pictures of the brain and spinal cord using magnets and radio waves. It can show the size, location, and characteristics of a tumor. Sometimes, a special dye called contrast is injected into a vein before the scan to make the tumor show up more clearly. Because ependymomas can occur in both the brain and spinal cord, doctors may order MRI scans of both areas to check for any spread of the disease.^[2]^[14]

In some cases, a computed tomography (CT) scan may be used, especially if an MRI is not available or if there are other medical reasons it cannot be done. A CT scan uses X-rays to create cross-sectional images of the body. While not as detailed as an MRI for brain and spinal cord tumors, a CT scan can still help identify abnormal growths.^[4]

Another test that may be performed is a lumbar puncture, also called a spinal tap. During this procedure, a thin needle is inserted into the lower spine to collect a sample of cerebrospinal fluid (CSF), the fluid that surrounds and cushions the brain and spinal cord. The fluid is then examined in a laboratory to look for tumor cells. This test helps determine whether the ependymoma has spread through the CSF to other parts of the central nervous system.^[14]

⚠️ Important

While imaging tests can strongly suggest the presence of an ependymoma, only a biopsy or surgical removal of the tumor can provide a definitive diagnosis. A small sample of the tumor tissue is examined under a microscope by a specialist called a neuropathologist, who identifies the type of cells and assigns a grade to the tumor based on how abnormal the cells look and how quickly they are likely to grow.

The biopsy is typically done during surgery, when the neurosurgeon removes as much of the tumor as safely possible. If the tumor cannot be fully removed due to its location near sensitive structures, at least a portion is taken for analysis. The tissue sample is studied to confirm the diagnosis of ependymoma and to determine its grade. Grades range from 1 to 3: Grade 1 tumors grow slowly and are considered low-grade, Grade 2 tumors also grow slowly but may be more likely to return after treatment, and Grade 3 tumors are fast-growing and malignant (cancerous).^[2]^[3]

In addition to grading, doctors now use molecular testing to examine the genetic features of the tumor. This newer approach looks at specific changes in the tumor’s DNA and helps classify the ependymoma into subtypes. Molecular subgroups can provide more accurate information about how the tumor will behave and how well it might respond to treatment. For example, ependymomas in different parts of the brain or spine may have different genetic signatures, and these differences can influence prognosis better than grade alone.^[2]^[11]

Doctors also look at the tumor’s location when making a diagnosis. Ependymomas in the brain are often described as being in the supratentorial region (upper two-thirds of the brain) or the infratentorial region (lower third of the brain, including the cerebellum and brainstem). Spinal ependymomas occur along the spinal cord. Each location can have different characteristics and may require different treatment approaches.^[6]^[15]

Putting all of this information together—symptoms, neurological exam findings, imaging results, biopsy analysis, and molecular testing—allows doctors to make an accurate diagnosis and develop a personalized treatment plan. Understanding the specific type and grade of ependymoma is essential because it helps predict how the tumor will behave and guides decisions about surgery, radiation, chemotherapy, or other therapies.^[13]

Diagnostics for Clinical Trial Qualification

When a patient with malignant ependymoma is being considered for a clinical trial, additional or more detailed diagnostic tests may be required. Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to fight cancer. To ensure that the trial results are accurate and meaningful, researchers need to carefully select participants who meet specific criteria.^[7]

One of the main requirements for enrolling in a clinical trial is having a confirmed diagnosis of ependymoma. This means that a biopsy or surgical sample must have been examined by a neuropathologist, and the diagnosis must be documented. In many cases, the pathology slides or tissue samples are reviewed again by experts at the clinical trial site to confirm the diagnosis and ensure that the tumor meets the study’s criteria.^[2]

Imaging tests, particularly MRI scans, are standard requirements for clinical trial enrollment. Researchers use baseline MRI images to measure the size and extent of the tumor before treatment begins. These images are then compared to scans taken during and after treatment to see if the tumor is shrinking, staying the same, or growing. For this reason, having high-quality MRI scans of both the brain and spine is often necessary before joining a trial.^[11]

Some clinical trials also require testing of cerebrospinal fluid to check whether tumor cells are present. This is especially important for studies focused on tumors that have spread or are at high risk of spreading through the CSF. A lumbar puncture may be repeated at different points during the trial to monitor changes in the CSF.^[14]

In recent years, molecular and genetic testing has become increasingly important for clinical trial eligibility. Many newer trials are designed for patients whose tumors have specific genetic mutations or features. For example, some trials may only accept patients with certain molecular subtypes of ependymoma, such as those with RELA fusion-positive or YAP1 fusion-positive tumors. These genetic markers are identified through laboratory tests on tumor tissue, and the results help researchers match patients to the most appropriate studies.^[2]^[11]

Other tests that may be required include blood work to check organ function, especially the kidneys, liver, and bone marrow. Clinical trials often have strict criteria about how well these organs are working because some experimental treatments can affect them. Patients must be healthy enough to tolerate the new treatment being tested.^[7]

Performance status is another factor considered during clinical trial screening. Doctors assess how well the patient is able to carry out daily activities. This is often measured using standardized scales that rate a person’s ability to care for themselves, work, and stay active. Patients who are too weak or sick may not be eligible for certain trials because the treatment could be too demanding.^[17]

Age can also be a factor in clinical trial eligibility. Some trials are designed specifically for children, others for adults, and some for both. The diagnostic process may differ slightly depending on the age of the patient, but the overall goal remains the same: to gather detailed information about the tumor and the patient’s health to determine if they are a good match for the study.^[7]

⚠️ Important

Enrolling in a clinical trial requires thorough documentation and communication between the patient’s care team and the trial coordinators. It’s important to ask questions about what tests are needed, why they are necessary, and what the results might mean for eligibility. Patients and families should also understand that meeting the diagnostic criteria does not guarantee acceptance into a trial, as other factors such as trial capacity and timing also play a role.

Because ependymomas are rare, finding and joining a clinical trial can be a valuable option for accessing new treatments that are not yet widely available. Diagnostic testing for trial qualification ensures that the study is conducted safely and that the results will be useful for future patients. For those who qualify, participating in a trial can offer hope and the chance to contribute to advancing medical knowledge about this challenging disease.^[7]^[17]

Prognosis and Survival Rate

Prognosis

The prognosis for patients with malignant ependymoma depends on several factors, including the grade of the tumor, its location, the patient’s age, and how much of the tumor can be removed during surgery. The most important factor affecting long-term survival is the extent of tumor resection. Patients who have a complete surgical removal of the tumor tend to have better outcomes than those with only partial removal. The location of the tumor also plays a significant role—tumors in certain areas of the brain or spinal cord may be harder to remove completely without causing damage to surrounding tissue.^[18]

Molecular features and subtypes of ependymoma are increasingly recognized as important predictors of prognosis. Some molecular subtypes are associated with more aggressive behavior and a higher risk of recurrence, while others have a more favorable outlook. For example, posterior fossa group A ependymomas tend to have a worse prognosis compared to posterior fossa group B. Understanding the molecular characteristics of the tumor helps doctors provide more accurate prognostic information and tailor treatment plans accordingly.^[2]^[11]

Age is another factor that influences prognosis. Younger children, especially those under the age of three, may face greater challenges with treatment and recovery. However, with advances in surgical techniques, radiation therapy, and supportive care, outcomes have been improving over time. Adults with spinal cord ependymomas, particularly low-grade tumors, often have a better prognosis compared to those with high-grade brain tumors.^[3]

Recurrence is a concern for many patients with ependymoma. Even after successful treatment, the tumor can return, either at the original site or elsewhere in the central nervous system. Regular follow-up with MRI scans and careful monitoring is essential to detect recurrence early and begin treatment promptly. The risk of recurrence varies depending on the tumor’s grade and subtype.^[7]

Survival Rate

Survival rates for malignant ependymoma vary widely depending on the factors mentioned above. For low-grade ependymomas (Grade 1 and 2), the prognosis is generally more favorable, with many patients achieving long-term survival or even cure, especially if the tumor is completely removed. However, Grade 3 (anaplastic) ependymomas are more aggressive and have a higher risk of recurrence and poorer outcomes.^[3]^[12]

Specific survival statistics for ependymoma are difficult to generalize because the disease is rare and outcomes depend on many individual factors. Studies have shown that patients who receive radiation therapy after incomplete tumor removal may have improved progression-free and overall survival compared to those who do not receive radiation. The addition of adjuvant therapy, such as radiation, is often recommended for higher-grade tumors or when complete resection is not possible.^[13]^[18]

It’s important to remember that survival statistics are based on large groups of patients and may not predict what will happen for any individual person. Every patient’s situation is unique, and advances in treatment continue to improve outcomes. Open communication with the healthcare team and access to specialized centers with expertise in treating ependymomas can make a significant difference in prognosis and quality of life.^[19]^[21]

#1 Clinical Trials Search in Europe